{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:55:28Z","timestamp":1791006928414,"version":"4.1.0"},"reference-count":15,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.26032","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:11:04Z","timestamp":1787955064000},"page":"260-271","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein\u2013Barr virus-positive classic Hodgkin lymphoma with rituximab"],"prefix":"10.3960","volume":"66","author":[{"given":"Satoshi","family":"Ichikawa","sequence":"first","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"},{"name":"Medical Student, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kanba","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Fujita","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Okitsu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyoshi","family":"Fujishima","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Pathology, Tohoku Medical and Pharmaceutical University, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kameoka","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Henter JI. Hemophagocytic lymphohistiocytosis. N Engl J Med. 2025; 392: 584-598.","DOI":"10.1056\/NEJMra2314005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 M\u00e9nard F, Besson C, Rinc\u00e9 P <i>et al.<\/i> Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis. 2008; 47: 531-534.","DOI":"10.1086\/590152"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Hagihara M, Inoue M, Hua J, Iwaki Y. Lymphocyte-depleted Hodgkin lymphoma complicating hemophagocytic lymphohistiocytosis as an initial manifestation: a case report and review of the literature. Intern Med. 2012; 51: 3067-3072.","DOI":"10.2169\/internalmedicine.51.8275"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Jin Z, Wang Y, Wei N, Wang Z. Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis-a dangerous disease. Ann Hematol. 2020; 99: 1575-1581.","DOI":"10.1007\/s00277-020-04093-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Henter JI, Horne A, Aric\u00f3 M <i>et al.<\/i> HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48: 124-131.","DOI":"10.1002\/pbc.21039"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Setiadi A, Zoref-Lorenz A, Lee CY, Jordan MB, Chen LYC. Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol. 2022; 9: e217-e227.","DOI":"10.1016\/S2352-3026(21)00366-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Knauft J, Schenk T, Ernst T <i>et al.<\/i> Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia. 2024; 38: 235-249.","DOI":"10.1038\/s41375-024-02135-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ichikawa S, Takahashi T, Katsushima H <i>et al.<\/i> Advanced lymphocyte-rich classical Hodgkin lymphoma complicated with fatal hemophagocytic syndrome. Intern Med. 2016; 55: 191-196.","DOI":"10.2169\/internalmedicine.55.5942"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Aldinucci D, Borghese C, Casagrande N. Formation of the immunosuppressive microenvironment of classic Hodgkin lymphoma and therapeutic approaches to counter it. Int J Mol Sci. 2019; 20: 2416.","DOI":"10.3390\/ijms20102416"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Chellapandian D, Das R, Zelley K <i>et al.<\/i> Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013; 162: 376-382.","DOI":"10.1111\/bjh.12386"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Marsh RA. Epstein\u2013Barr virus and hemophagocytic lymphohistiocytosis. Front Immunol. 2017; 8: 1902.","DOI":"10.3389\/fimmu.2017.01902"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Meng GQ, Wang JS, Wang YN, Wei N, Wang Z. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection. Int Immunopharmacol. 2021; 96: 107606.","DOI":"10.1016\/j.intimp.2021.107606"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hu S, Bansal P, Lynch D, Rojas Hernandez CM, Dayao Z. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature. J Med Case Rep. 2016; 10: 365.","DOI":"10.1186\/s13256-016-1143-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Boland PJ, Hegerova LT, Williams SJ <i>et al.<\/i> Successful treatment of two cases of classical Hodgkin lymphoma-associated hemophagocytic lymphohistiocyosis with R-CEPP. Leuk Lymphoma. 2017; 58: 478-481.","DOI":"10.1080\/10428194.2016.1193857"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kasamon YL, Jacene HA, Gocke CD <i>et al.<\/i> Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012; 119: 4129-4132.","DOI":"10.1182\/blood-2012-01-402792"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/3\/66_26032\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:34:54Z","timestamp":1791005694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/3\/66_26032\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.26032","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"26032"}}